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and between countries.  
2) This variation will relate to patient factors, disease-related 
factors, and treatment factors. 
3)  That regional variation in need for radiotherapy for lung 
cancer predicted by the MALTHUS model will be greater than 
that seen with a benchmark approach to optimal utilization.  
Methods:  The MALTHUS model for radiotherapy demand will be 
utilized in order to investigate factors associated with regional 
variation in need for radiotherapy for lung cancer patients. 
MALTHUS decision trees for 23 disease sites have been 
established. The proximal branches of the tree encodes for 
cancer site, stage distribution, and treatment modality 
indication. Distal branches contain detailed information about 
how radiation is delivered, such as fractionation. MALTHUS takes 
into account local variation in cancer incidence, disease stage, 
performance status, and co-morbidity. It draws on high-quality 
cancer incidence data collected from national Cancer Registries 
and the National Cancer Intelligence Network (NCIN). It 
simulates demand at local, regional and national levels, and 
draws comparisons with actual radiotherapy activity from the 
British National Health Service’s (NHS) Radiotherapy Dataset 
(RTDS). The resulting data can be used to study the effects of 
differences in clinical opinion over best practice, and can assist 
local oncologists and service managers in developing and 
assessing business plans.  
We will update the British data with direct access to the National 
Cancer Intelligence Database that, from previous work, has been 
properly curated for the use of this model. Data will be stratified 
for age, tumor characteristics, stage distribution, and region 
subdivided at the county level. The model will then be adapted 
to the appropriate treatment indications and dose fractionations 
using national evidence based best practice guidelines. 
We will quantify the influence of patient-related factors (age, 
sex, comorbidity, functional status), disease-related factors 
(cancer incidence, cancer stage), and treatment factors 
(hypofractionation including usage of SBRT) on regional (NHS 
Primary Care Trust level) demand for radiotherapy for lung 
cancer. In univariate analysis, factors will be defined 
categorically and demand for radiotherapy by variable category 
will be described. The influence of these factors will be further 
investigated in univariate sensitivity analysis. The consequences 
of applying regional extremes in each variable’s distribution on 
national radiotherapy demand will be considered. For 
multivariate sensitivity analysis, a Monte Carlo (MC) simulation 
method will be utilized.  Confidence intervals from MC simulation 
will be compared against ranges of proposed evidence-based 
benchmarks to compare model performance and precision. 
Potential differences in the influence of key factors influencing 
demand may exist between countries. As a second phase, we 
anticipate to adapt the model to the population of lung cancer 
patients in Ontario for comparison of outcomes. Population-
based data from the Ontario Cancer Registry (OCR) will be 
utilized. This will include data on cancer incidence, and 
collaborative stage information. Data on age distribution by 
county from OCR will be used to estimate regional differences in 
performance status and comorbidity. 
Significance: A primary benefit of this model is its potential to 
elucidate what influences demand for radiotherapy patients. 
Demand, and by the same token, wait lists, are affected by an 
increase in the incidence of cancer, by the increase in the 
referral of patients for radiotherapy, and by an increase in dose 
fractionation per course of radiotherapy. All of these factors are 
reflected in the MALTHUS. As the public system has a fixed global 
budget and lacks the reserve needed to expand capacity quickly 
in radiotherapy, an accurate prediction of future demand is vital 
in our situation. Comparing Canadian and British data utilizing 
MALTHUS should increase generalizability in its projections and 
may identify national differences in the impact of key factors 
driving demand. Reliable, well-characterized models are 
needed, as it can take years in working closely with policy makers 
in order to influence officials to provide adequate capacity for 
high-precision radiotherapy.  
Radiation therapy has major oncological benefits, and small 
incremental gain in health system performance can translate into 
large societal benefits. Health Services Research in its nascent 
stages in the field of Radiation Therapy, therefore there is a 
significant amount of knowledge and skills that can be gained by 
young investigators. Results of this research program will have a 
direct link to many global institutions. ESTRO and QUARTS are 
currently exploring optimal infrastructure for radiation therapy 
around Europe, a project funded by the European Commission. 
Moreover, this comparative analysis will supplement data 
utilized for Activity Based Costing and Cost Benefit research that 
ESMO is currently undertaking.  
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Purpose: Current lung parenchyma dose reduction strategies do 
not take into account the relative contribution of different lung 
regions. The addition of functional information at the time of 
treatment planning could preferentially save the most functional 
parts and reduce the risk of toxicity. The purpose of this study 
was to quantify lung function based on a DECT-derived iodine 
map in patients treated with radiotherapy for lung cancer, as 
well as to assess the dosimetric impact of its integration in 
radiotherapy planning.  
Methods and Materials: Patients treated with stereotactic 
ablative radiotherapy (SABR) for early stage or intensity-
modulated radiotherapy (IMRT) for locally advanced lung cancer 
were prospectively enrolled in this study. A DECT in treatment 
position was obtained at time of treatment planning. Single 
Photon Emission Computed Tomography / Computed 
Tomography (SPECT/CT) and pulmonary function tests were 
obtained for validation purposes. Relative contribution of each 
voxel to the total lung function was based on iodine 
concentration. Composition of each voxel was determined with 
a Matlab (MathWorks) script based on a three material 
decomposition. The functional map was integrated in treatment 
planning system using 6 sub-volumes of varying iode 
concentration levels. Percent lung volume receiving 5 Gy (V5), 
V20 and mean dose (MLD) to whole lungs (anatomical) versus 
functional lungs were compared using bilateral paired Student T 
tests.  
Results: Results from 20 consecutive patients, including 16 
patients treated with SABR and four patients with IMRT, are 
presented. Sixty percent had known chronic obstructive 
pulmonary disease. Median forced expiratory volume in one 
second was 62% of predicted (29-113%) and median diffusing 
capacity of the lung for carbon monoxide was 56% (39-91%). 
There was a strong correlation between DECT and SPECT/CT-
derived lung function (r = 0.8, p = 0.0001). Mean V5, V20 and 
MLD variation between functional (weighted dosimetry) and 
anatomical lung volumes was 16% (0-48%, p = 0.03), 5% (1-15%, p 
= 0.12) and 15% (1-43%, p = 0.047), respectively.  
Conclusions: DECT-derived iodine map correlates well with 
SPECT/CT and its integration in treatment planning is associated 
with significant differences in V5 and mean dose to functional 
lungs. Future work will focus on selection of patients most likely 
to benefit from function-sparing IMRT. 
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